Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.
Also called NCT07537088
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 468 participants
- Registry
-
NCT07537088
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07537088. Randomized; no masking; primary purpose treatment. Start 2026-05 (anticipated); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- SGLT2i
- Intervention (Drug)
- Finerenone
- Lead sponsor
- First Affiliated Hospital of Wannan Medical College
Record details
- Record id
cardio:ct-nct07537088- Content hash
7c962b561aaba63eed43f35df2f295e7919d1064860dcbbba1d4eb48f2d2d045